ITI-333
- Generic Name
- ITI-333
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05732194
- Locations
- 🇺🇸
Clinical Site 1, Miami, Florida, United States
A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05470101
- Locations
- 🇺🇸
Clinical Site 2, Creve Coeur, Missouri, United States
🇺🇸Clinical Site 1, Saint Louis, Missouri, United States
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Intra-Cellular Therapies, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04934124
- Locations
- 🇺🇸
Clinical Site, Eatontown, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath